127 related articles for article (PubMed ID: 1372353)
1. Specific antibody responses to synthetic peptides of HIV-1 p17 correlate with different stages of HIV-1 infection.
Jiang JD; Chu FN; Naylor PH; Kirkley JE; Mandeli J; Wallace JI; Sarin PS; Goldstein AL; Holland JF; Bekesi JG
J Acquir Immune Defic Syndr (1988); 1992; 5(4):382-90. PubMed ID: 1372353
[TBL] [Abstract][Full Text] [Related]
2. Immune response and epitope mapping of a candidate HIV-1 p17 vaccine HGP30.
Boucher CA; Krone WJ; Goudsmit J; Meloen RH; Naylor PH; Goldstein AL; Sun DK; Sarin PS
J Clin Lab Anal; 1990; 4(1):43-7. PubMed ID: 1690277
[TBL] [Abstract][Full Text] [Related]
3. Decline in CTL and antibody responses to HIV-1 p17 and p24 antigens in HIV-1-infected hemophiliacs irrespective of disease progression. A 5-year follow-up study.
O'Toole CM; Lowdell MW; Chargelegue D; Colvin BT
AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1361-8. PubMed ID: 1281655
[TBL] [Abstract][Full Text] [Related]
4. Cross-clade p17 peptide recognition by antisera to HGP-30, a 30-amino acid synthetic peptide antigen from HIV type 1 p17.
Zimmerman DH; Ulrich JT; Wright C; Lloyd JP; Winship MD; Sarin PS
AIDS Res Hum Retroviruses; 1998 Jun; 14(9):741-9. PubMed ID: 9643374
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of antibodies to the core protein P17, a serological marker during HIV-1 infection.
Mehta SU; Rupprecht KR; Hunt JC; Kramer DE; McRae BJ; Allen RG; Dawson GJ; Devare SG
AIDS Res Hum Retroviruses; 1990 Apr; 6(4):443-54. PubMed ID: 1692727
[TBL] [Abstract][Full Text] [Related]
6. Prevalence and persistence of antibody titers to recombinant HIV-1 core and matrix proteins in HIV-1 infection.
Janvier B; Mallet F; Cheynet V; Dalbon P; Vernet G; Besnier JM; Choutet P; Goudeau A; Mandrand B; Barin F
J Acquir Immune Defic Syndr (1988); 1993 Aug; 6(8):898-903. PubMed ID: 8315575
[TBL] [Abstract][Full Text] [Related]
7. Preclinical and clinical studies on immunogenicity and safety of the HIV-1 p17-based synthetic peptide AIDS vaccine--HGP-30-KLH.
Naylor PH; Sztein MB; Wada S; Maurer S; Holterman D; Kirkley JE; Naylor CW; Zook BC; Hitzelberg RA; Gibbs CJ
Int J Immunopharmacol; 1991; 13 Suppl 1():117-27. PubMed ID: 1823903
[TBL] [Abstract][Full Text] [Related]
8. Characterization of monoclonal antibodies against the human immunodeficiency virus matrix protein, p17gag: identification of epitopes exposed at the surfaces of infected cells.
Shang F; Huang H; Revesz K; Chen HC; Herz R; Pinter A
J Virol; 1991 Sep; 65(9):4798-804. PubMed ID: 1714518
[TBL] [Abstract][Full Text] [Related]
9. HIV-1 p17 synthetic peptide vaccine HGP-30: induction of immune response in human subjects and preliminary evidence of protection against HIV challenge in SCID mice.
Sarin PS; Mora CA; Naylor PH; Markham R; Schwartz D; Kahn J; Heseltine P; Gazzard B; Youle M; Rios A
Cell Mol Biol (Noisy-le-grand); 1995 May; 41(3):401-7. PubMed ID: 7580834
[TBL] [Abstract][Full Text] [Related]
10. A phase I study of HGP-30, a 30 amino acid subunit of the human immunodeficiency virus (HIV) p17 synthetic peptide analogue sub-unit vaccine in seronegative subjects.
Kahn JO; Stites DP; Scillian J; Murcar N; Stryker R; Volberding PA; Naylor PH; Goldstein AL; Sarin PS; Simmon VF
AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1321-5. PubMed ID: 1466950
[TBL] [Abstract][Full Text] [Related]
11. HGP-30, a synthetic analogue of human immunodeficiency virus (HIV) p17, is a target for cytotoxic lymphocytes in HIV-infected individuals.
Achour A; Picard O; Zagury D; Sarin PS; Gallo RC; Naylor PH; Goldstein AL
Proc Natl Acad Sci U S A; 1990 Sep; 87(18):7045-9. PubMed ID: 1698289
[TBL] [Abstract][Full Text] [Related]
12. Induction of cross clade reactive specific antibodies in mice by conjugates of HGP-30 (peptide analog of HIV-1(SF2) p17) and peptide segments of human beta-2-microglobulin or MHC II beta chain.
Zimmerman DH; Lloyd JP; Heisey D; Winship MD; Siwek M; Talor E; Sarin PS
Vaccine; 2001 Sep; 19(32):4750-9. PubMed ID: 11535326
[TBL] [Abstract][Full Text] [Related]
13. Neutralizing antibodies as a prognostic indicator in the progression of acquired immune deficiency syndrome (AIDS)-related disorders: a double-blind study.
Sei Y; Tsang PH; Roboz JP; Sarin PS; Wallace JI; Bekesi JG
J Clin Immunol; 1988 Nov; 8(6):464-72. PubMed ID: 3146584
[TBL] [Abstract][Full Text] [Related]
14. Human immunodeficiency virus contains an epitope immunoreactive with thymosin alpha 1 and the 30-amino acid synthetic p17 group-specific antigen peptide HGP-30.
Naylor PH; Naylor CW; Badamchian M; Wada S; Goldstein AL; Wang SS; Sun DK; Thornton AH; Sarin PS
Proc Natl Acad Sci U S A; 1987 May; 84(9):2951-5. PubMed ID: 2437588
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant properties of montanide CSA 720 with a recombinant HIV P17 gag protein and synthetic peptide antigens.
Kirkley JE; Goldstein AL; Naylor PH
Scand J Immunol; 1996 Apr; 43(4):431-8. PubMed ID: 8668923
[TBL] [Abstract][Full Text] [Related]
16. Immunodominant epitopes of HIV-1 p17 and p24.
Graham S; Follett EA; Wallace L; Desselberger U; Marsden HS
AIDS Res Hum Retroviruses; 1992 Oct; 8(10):1781-8. PubMed ID: 1280955
[TBL] [Abstract][Full Text] [Related]
17. Immunization of human HIV-seronegative volunteers with recombinant p17/p24:Ty virus-like particles elicits HIV-1 p24-specific cellular and humoral immune responses.
Martin SJ; Vyakarnam A; Cheingsong-Popov R; Callow D; Jones KL; Senior JM; Adams SE; Kingsman AJ; Matear P; Gotch FM
AIDS; 1993 Oct; 7(10):1315-23. PubMed ID: 8267904
[TBL] [Abstract][Full Text] [Related]
18. Antibody recognition of synthetic peptides mimicking immunodominant regions of HIV-1 p24 and p17 proteins.
Lottersberger J; Salvetti JL; Beltramini LM; Tonarelli G
Rev Argent Microbiol; 2004; 36(4):151-7. PubMed ID: 15786866
[TBL] [Abstract][Full Text] [Related]
19. Fine specificity of IgG subclass response to group antigens in HIV-1-infected patients.
Broliden PA; Morfeldt-MÃ¥nsson L; Rosen J; Jondal M; Wahren B
Clin Exp Immunol; 1989 May; 76(2):216-21. PubMed ID: 2503275
[TBL] [Abstract][Full Text] [Related]
20. Three antigenic regions in p17 of human immunodeficiency virus type 1 (HIV-1) revealed by mouse monoclonal antibodies and human antibodies in HIV-1 carrier sera.
Liu X; Ota A; Watanabe M; Ueda S; Saitoh A; Shinagawa H; Nakata A; Kurimura T; Wang X; Zhao Y
Microbiol Immunol; 1995; 39(10):775-85. PubMed ID: 8577268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]